Search research articles
Contact Us
Filters
Showing results (331-340 of 464) with videos related to
Page
of 47
Sort By:
Gastroenterology
|
May 9, 2007
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial
Stephan R Targan, Brian G Feagan, Richard N Fedorak, et al.
Journal of Crohn'S & Colitis
|
September 11, 2021
The Relationship Between Endoscopic and Clinical Recurrence in Postoperative Crohn's Disease: A Systematic Review and Meta-analysis
Alessandro Ble, Cecilia Renzulli, Fabio Cenci, et al.
Alimentary Pharmacology & Therapeutics
|
April 27, 2022
Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study
Niels Vande Casteele, William J Sandborn, Brian G Feagan, et al.
The Lancet. Gastroenterology & Hepatology
|
November 19, 2021
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study
Severine Vermeire, Peter L Lakatos, Timothy Ritter, et al.
Gut
|
October 23, 2014
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
Niels Vande Casteele, Reena Khanna, Barrett G Levesque, et al.
The New England Journal of Medicine
|
November 4, 2005
Natalizumab induction and maintenance therapy for Crohn's disease
William J Sandborn, Jean Frédéric Colombel, Roberts Enns, et al.
The New England Journal of Medicine
|
December 13, 2005
Infliximab for induction and maintenance therapy for ulcerative colitis
Paul Rutgeerts, William J Sandborn, Brian G Feagan, et al.
Inflammatory Bowel Diseases
|
April 13, 2011
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies
Walter Reinisch, William J Sandborn, Paul Rutgeerts, et al.
The American Journal of Gastroenterology
|
November 19, 2021
Responsiveness of a Histologic Scoring System Compared With Peak Eosinophil Count in Eosinophilic Esophagitis
Christopher Ma, Vipul Jairath, Brian G Feagan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 22, 2021
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial
William J Sandborn, Rory Rebuck, Yuhua Wang, et al.
Page
of 47
Search research articles
Search
Showing results (331-340 of 464) with videos related to
Sort By:
Page
of 47
Gastroenterology
|
May 9, 2007
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial
Stephan R Targan, Brian G Feagan, Richard N Fedorak, et al.
Journal of Crohn'S & Colitis
|
September 11, 2021
The Relationship Between Endoscopic and Clinical Recurrence in Postoperative Crohn's Disease: A Systematic Review and Meta-analysis
Alessandro Ble, Cecilia Renzulli, Fabio Cenci, et al.
Alimentary Pharmacology & Therapeutics
|
April 27, 2022
Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study
Niels Vande Casteele, William J Sandborn, Brian G Feagan, et al.
The Lancet. Gastroenterology & Hepatology
|
November 19, 2021
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study
Severine Vermeire, Peter L Lakatos, Timothy Ritter, et al.
Gut
|
October 23, 2014
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
Niels Vande Casteele, Reena Khanna, Barrett G Levesque, et al.
The New England Journal of Medicine
|
November 4, 2005
Natalizumab induction and maintenance therapy for Crohn's disease
William J Sandborn, Jean Frédéric Colombel, Roberts Enns, et al.
The New England Journal of Medicine
|
December 13, 2005
Infliximab for induction and maintenance therapy for ulcerative colitis
Paul Rutgeerts, William J Sandborn, Brian G Feagan, et al.
Inflammatory Bowel Diseases
|
April 13, 2011
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies
Walter Reinisch, William J Sandborn, Paul Rutgeerts, et al.
The American Journal of Gastroenterology
|
November 19, 2021
Responsiveness of a Histologic Scoring System Compared With Peak Eosinophil Count in Eosinophilic Esophagitis
Christopher Ma, Vipul Jairath, Brian G Feagan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 22, 2021
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial
William J Sandborn, Rory Rebuck, Yuhua Wang, et al.
Page
of 47